A Strong Pipeline of Drugs Bodes Well for Radius Health

In July 2016, Radius entered into a preclinical collaboration with Takeda Pharmaceutical to evaluate a combination of the former’s elacestrant with the latter’s investigational drug TAK-228 in Phase 2b development for treating breast, endometrial, and renal cancer with the goal of potentially exploring such a combination in a clinical study.

In January 2016, Radius entered into a worldwide clinical collaboration with Novartis to evaluate the safety and efficacy of combining the former’s elacestrant with the latter’s ribociclib.

Notably, Radius Health makes up ~1.5% of the SPDR S&P Biotech ETF’s (XBI) total portfolio holdings.

In the next part of the series, we’ll take a look some of the key licensing agreements entered into by Radius Health.


View more information: https://marketrealist.com/2018/01/strong-pipeline-drugs-bodes-well-radius-health/

See more articles in category: Finance
See also  When Is XL Fleet Going Public?

Leave a Reply

Back to top button